Your GLP-1 Is Doing More to Your Brain Than You Think

Your brain runs on a chemical called dopamine, and dopamine does not actually make you feel good. That is the part most people get wrong. What dopamine does is make you want things, push you toward them, generate the drive to get up and pursue a reward before you have it. The pleasure you feel when you actually get the reward is a separate system entirely. Understanding that distinction is the whole key to understanding what GLP-1 drugs are doing to people's motivation, desire, and behavior in ways that are almost impossible to notice from the inside.

To understand why, you need the full map first.

GLP-1 stands for glucagon-like peptide-1, which is a hormone your gut releases after you eat and whose main job is to signal fullness to your brain. The drugs that mimic this hormone, semaglutide, tirzepatide, retatrutide, were designed to hit receptors in the hypothalamus and slow gastric emptying and suppress appetite. That is the intended mechanism. What researchers have been building a case for over the last several years is that GLP-1 receptors are not just in the hunger-regulating parts of the brain. They sit directly inside the brain's reward circuitry, in a region called the ventral tegmental area, or the VTA, which is the origin point of the brain's main dopamine system.

The VTA is where dopamine neurons live that project out to the regions that generate wanting, seeking, and motivation. When those neurons fire, you get the drive to pursue things, whether that is food, sex, novelty, or connection.

Here is where the mechanism gets specific. A 2025 study published in Science Advances found that GLP-1 receptor activation in the VTA does not directly suppress dopamine neurons. Instead, it increases the firing of something called GABA neurons, which are the brain's primary inhibitory neurons, meaning their job is to slow other neurons down. Those GABA neurons then suppress the dopamine neurons in the VTA. So the drug hits a brake pedal, the brake slows the engine, and the output drops. The researchers demonstrated this in the context of cocaine-seeking behavior, showing that the endogenous GLP-1 circuit engaged those VTA GABA neurons to reduce reward-seeking, which confirms this is not a theoretical pathway. It is a circuit the brain already uses, and the drug amplifies it.

Now here is what makes this clinically strange and why people miss it.

A separate 2025 study on semaglutide found that the drug reduced what researchers call "wanting," meaning the motivated drive to pursue a reward, without reducing what they call "liking," meaning the hedonic pleasure response when the reward actually arrives. The study found that reward collection behavior dropped, but the positive response to the reward itself did not. In some conditions, VTA dopamine activity during the consummatory phase actually increased.

What that means in practical terms is this: if you are on a GLP-1 drug and you have sex, it still feels good. The liking system is intact. What has been turned down is the wanting system, the part that generates spontaneous desire, the drive to initiate, the mental preoccupation that makes you think about it in the first place. And because nothing feels wrong in the moment, because the experience itself is not degraded, your brain registers no problem. There is no signal that something changed. You just gradually stop initiating, stop seeking, stop thinking about it. And because the decline is slow and the positive experiences still feel positive, most people never connect the behavior change to the drug.

That is exactly why the video description at the top of this article hit so many people. The person in that story did not notice his desire was gone. He noticed it came back.

The dopamine pathway may not be the only mechanism at work either. A 2026 clinical review in Obesity Pillars proposed that GLP-1 agonists also upregulate activity at something called the 5-HT2C receptor, which is a serotonin receptor whose activation is well-established as a driver of sexual side effects in SSRI antidepressants. If that mechanism is accurate, and the authors note it is theoretical at this point, then there may be two independent pathways both suppressing desire simultaneously. The dopamine wanting system is turned down through the VTA GABA circuit, and separately, serotonin signaling at the same receptor that causes SSRI-related sexual dysfunction is increased.

The same review also noted something that helps explain why this gets missed in clinical practice. People on these drugs often lose significant weight, and weight loss by itself tends to improve sexual function, libido, and mood. So the drug is suppressing desire through one mechanism while the weight loss is improving it through another, and the two effects partially cancel out. The net result often looks like nothing, or even a small improvement, on a standard questionnaire. The camouflage is almost perfect.

There is also a null result worth including here for context. A 2024 randomized controlled trial of dulaglutide in healthy eugonadal men over four weeks found no significant change in sexual function scores compared to placebo. Dulaglutide is a weaker GLP-1 agonist with significantly lower CNS penetration than semaglutide, and four weeks may be too short a window to detect gradual behavioral drift. But it is a real finding and it suggests the effect may not be uniform across all drugs in this class or all populations.

The reversibility question is the practical one. The half-life of semaglutide is approximately seven days, which means within four to five half-lives, roughly four to five weeks after stopping, plasma levels drop to near zero and receptor signaling returns toward baseline. The reward pathway suppression is not structural, it is pharmacological, so it lifts with clearance. Clinical reports are consistent with this, people describe drive returning in a way that feels sudden, because it was actually being continuously suppressed and then simply stopped being.

The broader implication here matters beyond libido. The same 2025 semaglutide trial in JAMA Psychiatry that found the drug reduced alcohol consumption in people with alcohol use disorder, including craving, heavy drinking days, and overall intake in a randomized controlled trial of 48 participants, was demonstrating the same mechanism. The VTA GABA pathway the drug activates does not distinguish between wanting alcohol, wanting sex, wanting to start a new project, or wanting to call a friend. It is general motivational drive. The drug is not selectively reducing appetite. It is reducing the wanting signal across the board, and appetite is just the context in which it was designed and studied.

That is worth sitting with for a moment. When you change the gain on a system that governs wanting, you do not change it for one thing. You change it for everything the system serves.

---

References

1. Merkel R, Thapa N, Engel L, et al. 2025. An endogenous GLP-1 circuit engages VTA GABA neurons to regulate mesolimbic dopamine neurons and attenuate cocaine seeking. Science Advances, 119, eadr5051. Finding: GLP-1 receptor activation in the VTA increases GABA neuron firing, which suppresses dopamine neuron activity and reduces reward-seeking behavior. Source
2. Hurst K, et al. 2025. GLP-1 receptor agonist semaglutide reduces appetite while increasing dopamine reward signaling. Neurobiology of Disease and Treatment. Finding: Semaglutide reduced reward collection but did not diminish hedonic "liking" response, and actually enhanced VTA dopamine activity during consummatory phase. Source
3. Gelfand SG, Tveit RL, Simon JA. 2026. Clinical review of how glucagon-like peptide-1 agonist obesity medications decrease sexual desire, and a biopsychosocial model for why we don't 'see' it. Obesity Pillars, 17, 100233. Finding: GLP-1 agonists likely decrease sexual desire via 5-HT2C serotonergic upregulation same mechanism as SSRIs, but this is camouflaged by competing positive effects of weight loss. Source
4. Hendershot CS, et al. 2025. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry, 824, 395-405. Finding: Semaglutide reduced alcohol consumption, craving, and heavy drinking days in a Phase 2 RCT n=48, confirming reward pathway modulation extends beyond appetite. Source
5. Jalleh RJ, et al. 2024. Effects of the glucagon-like peptide-1 receptor agonist dulaglutide on sexuality in healthy men: a randomised, double-blind, placebo-controlled crossover study. eBioMedicine, 107. Finding: 4-week dulaglutide in healthy eugonadal men showed no change in sexual function scores null result, but short duration and weaker CNS penetration than semaglutide. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness